The role of lesional T cells in recalcitrant psoriasis during infliximab therapy

European Journal of Dermatology

Volumn 15, Issue 6, 2005, Pages 454-458

  Bovenschen, H J ^a   Van De Kerkhof, P C M ^a   Gerritsen, W J ^a   Seyger, M M B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti TNF ; Infliximab; NK T cells; Psoriasis; T cell subsets

Indexed keywords

CD4 ANTIGEN; CD94 ANTIGEN; INFLIXIMAB;

ADULT; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL EXAMINATION; CORRELATION ANALYSIS; DISEASE EXACERBATION; DRUG EFFICACY; EPIDERMIS; EPIDERMIS CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NATURAL KILLER CELL; PSORIASIS VULGARIS; SKIN BIOPSY; T LYMPHOCYTE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MIDDLE AGED; PSORIASIS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 28244455798     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23.
2. Pastore S, Mascia F, Mariotti, Dattilo C, Girolomoni G. Chemokine networks in inflammatory skin diseases, Eur J Dermatol 2004; 14(4): 203-8.
3. Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards III CK. Biology of tumor necrosis factor-α - implications for psoriasis. Exp Dermatol 2004; 13: 193-222.
4. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 2001; 357: 1842-7.
5. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-42.
6. Bovenschen HJ, Seyger MM, van de Kerkhof PC. Plaque psoriasis versus atopic dermatitis and lichen planus: A comparison for lesional T cell subsets, epidermal proliferation and differentiation. Br J Dermatol 2005; 153(1): 72-8.
7. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
8. Bos JD, Zonneveld I, Das PK, et al. The skin immune system (SIS): distribution and immunophenotype of lymphocyte subpopulations in normal human skin. J Invest Dermatol 1987; 88: 569-73.
9. Vissers WH, Roelofzen J, De Jong EM, Van Erp PE, Van de Kerkhof PC. Flexural versus plaque lesions in psoriasis: an immunohistochemical differentiation. Eur J Dermatol 2005; 15(1): 13-7.
10. Nickoloff BJ, Wrone-Smith T, Bonish B, Porcelli SA. Response of murine and normal skin to injection of allogeneic blood-derived psoriatic immunocytes: detection of T cells expressing receptors typically present on natural killer cells including CD94, CD 158, and CD161. Arch Dermatol 1999; 135: 546-52.
11. Nickoloff BJ. Skin innate immune system in psoriasis: friend or foe? J Clin Invest 1999; 104: 1161-4.
12. Gottlieb AB, Masud S, Ramamurthi R, et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis. J Am Acad Dermatol 2003; 48: 68-75.
13. Van Deventer SJ. Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology 2001; 121: 1242-6.
14. Smeets TJ, Kraan MC, van Loon ME, Tak PP. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003; 48: 2155-62.